ERBB2 and ovarian carcinoma: They then compared [89Zr]Zr-2,3-HOPO-p-Phe-NCS-trastuzumab and [89Zr]Zr-DFO-trastuzumab in a HER2/neu mouse model of ovarian carcinoma using small animal PET/CT imaging.